Septerna Inc
SEPN
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.7B
$36.75
▼ -0.14%
P/E
-68.06
Mkt Cap
$1.7B
52-Wk Range
$13.67–$51.10
52-Week Range
$13.67 - $51.10
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 150.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary GPCR drug discovery and development platform enabling oral small molecule candidates for traditionally difficult targets
- Experienced management team with deep expertise in GPCR biology and clinical development
- First-mover advantage in oral formulations for specific GPCR indications with limited treatment options
- Diversified pipeline across high-value therapeutic areas with significant market opportunities
Bear Case
1 risk
- High volatility (beta 2.3). Larger-than-normal price swings expected.
Growth
Stable outlook
Clinical trial progression of SEP-786, SEP-631, and TSHR programs toward potential regulatory approvals
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Hot
+20.9% over 3m
Quality
Excellent
High-growth business (500% revenue growth, 100% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying SEPN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 10, 2026
Reported EPS of -$0.29 vs -$0.43 consensus (+31.9% surprise). Revenue of $26.7M vs $19.2M expected (+39.1%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+31.9%
Revenue trend · last 8Q
—
+80%
-31%
-68%
+12113%
+11276%
+12011%
+22376%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$176.0K
$212.0K
$219.0K
$119.0K
$21.5M
$24.1M
$26.5M
$26.7M
Margins · last 8Q
Gross
0.0%
Operating
-63.0%
Profit
-48.7%
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 12, 2026
vs Industry
How SEPN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related